GMP issues for recombinant plant-derived pharmaceutical proteins

Biotechnology Advances

Volumn 30, Issue 2, 2012, Pages 434-439

  Fischer, Rainer ^a,b   Schillberg, Stefan ^a   Hellwig, Stephan ^a   Twyman, Richard M ^c   Drossard, Juergen ^a  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Biopharmaceuticals; GMP; Pharmaceuticals; Plants; Platform development

Indexed keywords

BIOPHARMACEUTICALS; CLINICAL DEVELOPMENT; GMP; GOOD MANUFACTURING PRACTICES; MAMMALIAN CELLS; MEDICAL USE; PHARMACEUTICAL PROTEIN; PLANT CELLS; PLANTS; PLATFORM DEVELOPMENT; PRODUCTION PROCESS; RECOMBINANT PROTEIN; REGULATORY GUIDELINES; STERILE ENVIRONMENTS; SUSPENSION CELL; SYNTHETIC MEDIUM; WHOLE PLANTS;

BIOREACTORS; DRUG PRODUCTS; MANUFACTURE;

RECOMBINANT PROTEINS;

RECOMBINANT PROTEIN;

BACTERIUM; BIOREACTOR; CYTOLOGY; DRUG; GUIDELINE; MAMMAL; MEDICINAL PLANT; PROTEIN;

BIOREACTOR; BIOSYNTHESIS; BIOTECHNOLOGY; GENETICS; LEGAL ASPECT; MEDICINAL PLANT; METABOLISM; METHODOLOGY; PLANT CELL; REVIEW; STANDARD; TRANSGENIC PLANT;

BIOREACTORS; BIOTECHNOLOGY; PLANT CELLS; PLANTS, GENETICALLY MODIFIED; PLANTS, MEDICINAL; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 84856948838     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.08.007     Document Type: Review

References (57)

1. Aviezer D., Almon-Brill E., Shaaltiel Y., Galili G., Chertkoff R., Hashmueli S., et al. Novel enzyme replacement therapy for Gaucher disease: ongoing Phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells. Mol Genet Metab 2009, 96:S13-S14.
2. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., Bartfeld D., Mizrachi S., et al. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS One 2009, 4:e4792.
3. Barta A., Sommergruber K., Thompson D., Hartmuth K., Matzke M., Matzke A. The expression of a nopaline synthase human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. Plant Mol Biol 1986, 6:347-357.
4. Bock R. Plastid biotechnology: prospects for herbicide and insect resistance, metabolic engineering and molecular farming. Curr Opin Biotechnol 2007, 18:100-106.
5. Castilho A., Strasser R., Stadlmann J., Grass J., Jez J., Gattinger P., et al. In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem 2010, 285:15923-15930.
6. Conley A.J., Joensuu J.J., Jevnikar A.M., Menassa R., Brandle J.E. Optimization of elastin-like polypeptide fusions for expression and purification of recombinant proteins in plants. Biotechnol Bioeng 2009, 103:562-573.
7. Conley A.J., Joensuu J.J., Richman A., Menassa R. Protein body-inducing fusions for high-level production and purification of recombinant proteins in plants. Plant Biotechnol J 2011, 9:419-433.
8. D'Aoust M.A., Lavoie P.O., Couture M.M., Trépanier S., Guay J.M., Dargis M., et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008, 6:930-940.
9. D'Aoust M.A., Couture M.M., Charland N., Trépanier S., Landry N., Ors F., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010, 8:607-619.
10. Decker E.L., Reski R. The moss bioreactor. Curr Opin Plant Biol 2004, 7:166-170.
11. Desai P., Shrivastava N., Padh H. Production of heterologous protein in plants: strategies for optimal expression. Biotechnol Adv 2010, 28:427-435.
12. EMEA Committee for Proprietary Medicinal Products (CPMP) Points to Consider on Quality Aspects of Medicinal Products Containing Active Substances Produced by Stable Transgene Expression in Higher Plants (EMEA/CPMP/BWP/764/02) 2002, EMA, London UK.
13. EMEA Committee for Proprietary Medicinal Products (CPMP) Guideline on the Quality of Biological Active Substances Produced by Stable Transgene Expression in Higher Plants (EMEA/CHMP/BWP/48316/2006) 2008, EMA, London UK.
14. FDA/USDA Draft guidance. Drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals. FDA, Rockville MD 2002, http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM055424.pdf.
15. Giritch A., Marillonnet S., Engler C., van Eldik G., Botterman J., Klimyuk V., et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 2006, 103:14701-14706.
16. Gomord V., Sourrouille C., Fitchette A.C., Bardor M., Pagny S., Lerouge P., et al. Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge. Plant Biotechnol J 2004, 2:83-100.
17. Gomord V., Fitchette A.C., Menu-Bouaouiche L., Saint-Jore-Dupas C., Plasson C., Michaud D., et al. Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol J 2010, 8:564-587.
18. Hellwig S., Drossard J., Twyman R.M., Fischer R. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 2004, 22:1415-1422.
19. Hiatt A.H., Caffertey R., Bowdish K. Production of antibodies in transgenic plants. Nature 1989, 342:76-78.
20. Hood E.E. From green plants to industrial enzymes. Enzyme & Microbial Technol 2002, 30:279-283.
21. Hood E.E., Witcher D.R., Maddock S., Meyer T., et al. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breeding 1997, 3:291-306.
22. Huang Z., Phoolcharoen W., Lai H., Piensook K., Cardineau G., Zeitlin L., et al. High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 2010, 106:9-17.
23. Joensuu J.J., Conley A.J., Lienemann M., Brandle J.E., Linder M.B., Menassa R. Hydrophobin fusions for high-level transient protein expression and purification in Nicotiana benthamiana. Plant Physiol 2010, 152:622-633.
24. Kusnadi A.R., Evangelista R.L., Hood E.E., Howard J.A., Nikolov Z.L. Processing of transgenic corn seed and its effect on the recovery of recombinant β-glucuronidase. Biotech Bioeng 1998, 60:44-52.
25. Ma J.K.C., Drake P.M.W., Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003, 4:794-805.
26. Ma J.K.C., Barros E., Bock R., Christou P., Dale P.J., Dix P.J., et al. Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep 2005, 6:593-599.
27. Ma J.K.C., Chikwamba R., Sparrow P., Fischer R., Mahoney R., Twyman R.M. Plant-derived pharmaceuticals - the road forward. Trends Plant Sci 2005, 10:580-585.
28. McCormick A.A., Reddy S., Reinl S.J., Cameron T.I., Czerwinkski D.K., Vojdani F., et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci USA 2008, 105:10131-10136.
29. Menkhaus T.J., Bai Y., Zhang C.M., Nikolov Z.L., Glatz C.E. Considerations for the recovery of recombinant proteins from plants. Biotechnol Prog 2004, 20:1001-1014.
30. Naqvi S., Ramessar K., Farre G., Sabalza M., Miralpeix B., Twyman R.M., et al. High value products from transgenic maize. Biotechnol Adv 2011, 29:40-53.
31. Nikolov Z.L., Woodard S.L. Downstream processing of recombinant proteins from transgenic feedstock. Curr Opin Biotechnol 2004, 15:479-486.
32. Pogue G.P., Vojdani F., Palmer K.E., Hiatt E., Hume S., Phelps J., et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 2010, 8:638-654.
33. Sainsbury F., Lomonossoff G.P. Extremely high-level and rapid protein production in plants without the use of viral replication. Plant Physiol 2008, 148:1212-1218.
34. Schahs M., Strasser R., Stadlmann J., Kunert R., Rademacher T., Steinkellner H. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotech J 2007, 5:657-663.
35. Schillberg S., Fischer R., Emans N. Molecular farming of recombinant antibodies in plants. Cell Mol Life Sci 2003, 60:433-445.
36. Shaaltiel Y., Bartfeld D., Hashmueli S., Baum G., Brill-Almon E., Galili G., et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 2007, 5:579-590.
37. Sharma A.K., Sharma M.K. Plants as bioreactors: recent developments and emerging opportunities. Biotechnol Adv 2009, 27:811-832.
38. Shoji Y., Bi H., Musiychuk K., Rhee A., Horsey A., Roy G., et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 2009, 27:1087-1092.
39. Shoji Y., Chichester J.A., Jones M., Manceva S.D., Damon E., Mett M., et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccine 2011, 7(Suppl 1/2):41-50.
40. Sijmons P.C., Dekker B.M.M., Schrammeijer B., Verwoerd T.C., van den Elzen P.J.M., Hoekema A. Production of correctly processed human serum albumin in transgenic plants. Bio/Technol 1990, 8:217-221.
41. Spok A., Twyman R.M., Fischer R., Ma J.K.C., Sparrow P.A.C. Evolution of a regulatory framework for plant-made pharmaceuticals. Trends Biotechnol 2008, 26:506-517.
42. Sriraman R., Bardor M., Sack M., Vaquero C., Faye L., Fischer R., et al. Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-α(1,3)-fucose residues. Plant Biotechnol J 2004, 2:279-287.
43. Strasser R., Altmann F., Mach L., Glossl J., Steinkellner H. Generation of Arabidopsis thaliana plants with complex N-glycans lacking beta1,2-linked xylose and core alpha1,3-linked fucose. FEBS Lett 2004, 561:132-136.
44. Strasser R., Stadlmann J., Schahs M., Stiegler G., Quendler H., Mach L., et al. Generation of glycoengineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotech J 2008, 6:392-402.
45. Strasser R., Castilho A., Stadlmann J., Kunert R., Quendler H., Gattinger P., et al. Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem 2009, 284:20479-20485.
46. Tacket C.O., Mason H.S., Losonsky G., Estes M.K., Levine M.M., Arntzen C.J. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000, 182:302-305.
47. Tiwari S., Verma P.C., Singh P.K., Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009, 27:449-467.
48. Torrent M., Llompart B., Lasserre-Ramassamy S., Llop-Tous I., Bastida M., Marzabal P., et al. Eukaryotic protein production in designed storage organelles. BMC Biol 2009, 7:5.
49. Triguero A., Cabrera G., Cremata J.A., Yuen C.T., Wheeler J., Ramírez N.I. Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol J 2005, 3:449-457.
50. Twyman R.M., Stoger E., Schillberg S., Christou P., Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotechnol 2003, 21:570-578.
51. Twyman R.M., Schillberg S., Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 2005, 10:185-218.
52. Vézina L.P., Faye L., Lerouge P., D'Aoust M.A., Marquet-Blouin E., Burel C., et al. Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotechnol J 2009, 7:442-455.
53. Whaley K.J., Hiatt A., Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Hum Vaccine 2011, 7:349-356.
54. Witcher D., Hood E., Peterson D., Bailey M., et al. Commercial production of β-glucuronidase (GUS): a model system for the production of proteins in plants. Mol Breeding 1998, 4:301-312.
55. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnol 2004, 22:1393-1398.
56. Xu J., Ge X., Dolan M.C. Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol Adv 2011, 29:278-299.
57. Yusibov V., Streatfield S.J., Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals. Vaccines, antibodies and beyond. Hum Vaccin 2011, 7:313-321.